154 related articles for article (PubMed ID: 7647079)
1. A comparison of placebo responders and nonresponders in subgroups of depressive disorder.
Bialik RJ; Ravindran AV; Bakish D; Lapierre YD
J Psychiatry Neurosci; 1995 Jul; 20(4):265-70. PubMed ID: 7647079
[TBL] [Abstract][Full Text] [Related]
2. Worsening of depressive symptoms prior to randomization in clinical trials: a possible screen for placebo responders?
Evans KR; Sills T; Wunderlich GR; McDonald HP
J Psychiatr Res; 2004; 38(4):437-44. PubMed ID: 15203296
[TBL] [Abstract][Full Text] [Related]
3. [Value of tianeptine in treating major recurrent unipolar depression. Study versus placebo for 16 1/2 months of treatment].
Daléry J; Dagens-Lafant V; De Bodinat C
Encephale; 1997; 23(1):56-64. PubMed ID: 9172969
[TBL] [Abstract][Full Text] [Related]
4. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
Alpert JE; Franznick DA; Hollander SB; Fava M
J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
[TBL] [Abstract][Full Text] [Related]
5. Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes?
Nierenberg AA; Pava JA; Clancy K; Rosenbaum JF; Fava M
Biol Psychiatry; 1996 Oct; 40(8):691-6. PubMed ID: 8894060
[TBL] [Abstract][Full Text] [Related]
6. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
Mouchabac S; Ferreri M; Cabanac F; Bitton M
Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
[TBL] [Abstract][Full Text] [Related]
7. Response of anxiety and agitation symptoms during nefazodone treatment of major depression.
Fawcett J; Marcus RN; Anton SF; O'Brien K; Schwiderski U
J Clin Psychiatry; 1995; 56 Suppl 6():37-42. PubMed ID: 7649972
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J
BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624
[TBL] [Abstract][Full Text] [Related]
9. Predictors of an acute antidepressant response to fluoxetine and sertraline.
Flament MF; Lane RM; Zhu R; Ying Z
Int Clin Psychopharmacol; 1999 Sep; 14(5):259-75. PubMed ID: 10529069
[TBL] [Abstract][Full Text] [Related]
10. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial.
Kasper S; Volz HP; Möller HJ; Dienel A; Kieser M
Eur Neuropsychopharmacol; 2008 Nov; 18(11):803-13. PubMed ID: 18694635
[TBL] [Abstract][Full Text] [Related]
11. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
[TBL] [Abstract][Full Text] [Related]
12. Factors that influence the outcome of placebo-controlled antidepressant clinical trials.
Niklson IA; Reimitz PE; Sennef C
Psychopharmacol Bull; 1997; 33(1):41-51. PubMed ID: 9133750
[TBL] [Abstract][Full Text] [Related]
13. Symptoms of anxiety in depression: assessment of item performance of the Hamilton Anxiety Rating Scale in patients with depression.
Vaccarino AL; Evans KR; Sills TL; Kalali AH
Depress Anxiety; 2008; 25(12):1006-13. PubMed ID: 18800370
[TBL] [Abstract][Full Text] [Related]
14. Follow-up and relapse analysis of an inositol study of depression.
Levine J; Barak Y; Kofman O; Belmaker RH
Isr J Psychiatry Relat Sci; 1995; 32(1):14-21. PubMed ID: 7622343
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients.
Mendels J; Reimherr F; Marcus RN; Roberts DL; Francis RJ; Anton SF
J Clin Psychiatry; 1995; 56 Suppl 6():30-6. PubMed ID: 7649971
[TBL] [Abstract][Full Text] [Related]
16. The persistence of the placebo response in antidepressant clinical trials.
Khan A; Redding N; Brown WA
J Psychiatr Res; 2008 Aug; 42(10):791-6. PubMed ID: 18036616
[TBL] [Abstract][Full Text] [Related]
17. Affective and anxiety comorbidity in post-traumatic stress disorder treatment trials of sertraline.
Brady KT; Clary CM
Compr Psychiatry; 2003; 44(5):360-9. PubMed ID: 14505296
[TBL] [Abstract][Full Text] [Related]
18. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials.
Khan A; Brodhead AE; Kolts RL; Brown WA
J Psychiatr Res; 2005 Mar; 39(2):145-50. PubMed ID: 15589562
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety.
Fawcett J; Barkin RL
J Clin Psychiatry; 1998 Mar; 59(3):123-7. PubMed ID: 9541155
[TBL] [Abstract][Full Text] [Related]
20. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
